🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congrats to Sizun Jiang & his BIDMC & Stanford Medicine team on their latest publication! See how they leveraged #MIBI to conduct multiplexed DNA, RNA & protein imaging in tissue + applied it to study the mechanisms & pathology of #HIV persistance. #PANINI x.com/SizunJ/status/…

As Genoa continues supporting category-defying companies Vikram Chaudhery has been promoted to the role of #partner We also welcome Amy Harris as VP of Finance to lead our fund administration and be a resource for portcos. Read more here: bwnews.pr/39XvTXD #venturecapital

Congratulations Genoa company Ionpath for its strategic investment from Thermo Fisher. We are proud to have been with you from the early days to broaden access to the world’s best spatial biology capabilities for drug discovery and translational medicine. #genoaportco

Join Genoa's Negin Mokhtari, PhD and fellow panelists at #AOBIO. May 26. Register here: oen.org/calendar-event… #venturecapital

Looking forward to seeing our portfolio companies InterVenn Biosciences and SimBioSys poster presentations at ASCO Annual Meeting June 3-7th #Cancerresearch #breastcancer #venturecapital #oncology #ASCO2022 #ASCO22

Don’t Miss Vikram Chaudhery Ph.D at Biotechnology Innovation Organization Annual Meeting in San Diego. He will be speaking on the panel discussion: The New Journey of a Data Point: Digital Innovation for a Powerful Purpose on 6/15. bio.org/events/bio-int… #BIO2022 #Venturecapital #funding #Biotechnology

The FNIH welcomes InterVenn as a new partner in the Biomarkers Consortium. We look forward to benefitting from their added insight and expertise. Learn more: fnih.org/our-programs/b…

Our #ASCO22 blog is up: "Huge ASCO Breakthroughs: But will these Innovations Advance #EquitableCancerCare?" simbiosys.com/huge-asco-brea…

#ICYMI Genoa Ventures Partner Vikram Chaudhery Ph.D is speaking today at 4:00PM PT on the panel discussion, The New Journey of a Data Point: Digital Innovation for a Powerful Purpose, in in Upper Level Session Room 6A #BIO2022 #Venturecapital #funding #Biotechnology

We're excited to be in #SFO for #FOCIS2022! Stop by to say hi & learn how our Multiplexed Ion Beam Imaging high-res tissue imaging tool can profile #TME to enhance #immunology + #immunotherapy research. Here are some #MIBI pubs to whet your appetite: ow.ly/AUwG50JCVJ0

Join Vikram Chaudhery speaking about Launching and Scaling Innovations in a Rapidly Changing Marketplace at the Sequencing to Function: Analysis and Applications for the Future Meeting on June 22nd. Register here: bit.ly/3NDsM69 #VentureCapital #scaling #growth

Today at 11:40 AM MDT Vikram Chaudhery presents Launching and Scaling Innovations in a Rapidly Changing Marketplace. At Sequencing to Function: Analysis and Applications for the Future Meeting. #VentureCapital #scaling #Growth

At #ESMOBreast22, we presented a state-of-the art technique to identify HER2-low patients. To Read more: bit.ly/3ag4Ozj #bcms #HER2low

Genoa closed our oversubscribed Fund II to continue investing where biology and technology converge. We are honored to have the support of our existing and new Limited Partners. Read more here: businesswire.com/news/home/2022… #Venturecapital #Biotech #venture #funding #genoaportco

Congratulations to Genoa Ventures portfolio company SimBioSys for its newest Advisory Board members. #genoaportco #venturecapital #WomenInScience businesswire.com/news/home/2022…

Congratulations to Genoa's portfolio company InterVenn Biosciences co-founder Carolyn Bertozzi, PhD and her award of the 2022 Nobel Prize in Chemistry! #2022NobelPrize #WomeninScience #biochemistry

"Tropic Biosciences is using genetic editing tools to create new varieties of important crops. In an era of climate change and climbing prices, these techniques could safeguard food supplies." Rhys Blakely thetimes.co.uk/article/dna-bi…

Congrats to Bryan Cannon, @kausaliavbosse, Bendall Lab & co for their BMC publication! To learn more about how they mapped protein markers w/ #MIBI to parse neurological disorders like #Alzheimers, check out our blog: ionpath.com/to-parse-neuro…

Genoa Ventures is proud of our investment in InterVenn Biosciences to help enable the Nobel Prize winning work of Dr. Carolyn Bertozzi in biomarker discovery research.

Congratulations to Ervin Estigarribia and Laura Beggrow on their appointments as CEO and COO of InterVenn Biosciences. We look forward to our continued work together moving precision medicine forward with glycoproteomics. #glycoproteomics #diagnotics